CO2017007046A2 - Mezcla de ácidos carboxilicos para tratar pacientes con insuficiencia renal - Google Patents

Mezcla de ácidos carboxilicos para tratar pacientes con insuficiencia renal

Info

Publication number
CO2017007046A2
CO2017007046A2 CONC2017/0007046A CO2017007046A CO2017007046A2 CO 2017007046 A2 CO2017007046 A2 CO 2017007046A2 CO 2017007046 A CO2017007046 A CO 2017007046A CO 2017007046 A2 CO2017007046 A2 CO 2017007046A2
Authority
CO
Colombia
Prior art keywords
renal
treatment
patients
acid
replacement therapy
Prior art date
Application number
CONC2017/0007046A
Other languages
English (en)
Inventor
Miramontes Jorge Antonio Hernández
Villanueva Jorge Alberto Hernández
Original Assignee
Hernandez Miramontes Jorge Antonio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56234463&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2017007046(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hernandez Miramontes Jorge Antonio filed Critical Hernandez Miramontes Jorge Antonio
Publication of CO2017007046A2 publication Critical patent/CO2017007046A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/20—Sebacic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Actualmente el tratamiento para pacientes con enfermedad renal terminal (estadio V) consiste en terapia renal sustitutiva (hemodiálisis, diálisis peritoneal o transplante renal); extraordinariamente costosa que conlleva una pobre calidad de vida. Nuestro invento es una mezcla de ácidos carboxílicos: ácido cítrico, ácido succínico, ácido fumárico y ácido málico, y cualesquiera de sus combinaciones posibles. Dicho producto se utiliza preferentemente vía oral o también vía intravenosa, en el tratamiento de pacientes con insuficiencia renal crónica, hiperamonemia o condiciones humanas que cursen con balance nitrogenado negativo. Este producto es benéfico para disminuir los valores séricos de urea y de amonio sérico, a la vez que por transaminación del oxalacetato formado vía succinato, fumarato y malato, promueve la biosíntesis de aminoácidos no esenciales; por transaminación del alfa ceto glutarato formado vía citrato, genera ácido glutámico y los aminoácidos relacionados al mismo como glutamina. Este tratamiento previene, preserva e inclusive mejora la función renal. En otros pacientes retarda el deterioro de la función renal y la imperiosa necesidad del tratamiento renal sustitutivo. En otros más, se utiliza como tratamiento complementario al tratamiento renal sustitutivo para mejorar la calidad de vida del paciente y mejorar los parámetros laboratoriales.
CONC2017/0007046A 2015-03-20 2017-07-13 Mezcla de ácidos carboxilicos para tratar pacientes con insuficiencia renal CO2017007046A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2015003641A MX357998B (es) 2015-03-20 2015-03-20 Una mezcla de acidos carboxilicos, especificamente acido citrico, acido succinico, acido fumarico y acido malico para el tratamiento de pacientes con insuficiencia renal cronica, insuficiencia renal aguda, hepatopatias agudas o cronicas que cursen con hiperamonemia, enfermedades congenitas con alteraciones enzimaticas en el ciclo de la urea, asi como condiciones clínicas que cursen con balance nitrogenado negativo.
PCT/MX2015/000144 WO2016153331A1 (es) 2015-03-20 2015-11-04 Mezcla de ácidos carboxilicos para tratar pacientes con insuficiencia renal

Publications (1)

Publication Number Publication Date
CO2017007046A2 true CO2017007046A2 (es) 2018-01-05

Family

ID=56234463

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0007046A CO2017007046A2 (es) 2015-03-20 2017-07-13 Mezcla de ácidos carboxilicos para tratar pacientes con insuficiencia renal

Country Status (26)

Country Link
US (2) US10688068B2 (es)
EP (1) EP3219315B1 (es)
JP (1) JP6771191B2 (es)
KR (1) KR102057555B1 (es)
CN (1) CN108024981B (es)
AU (1) AU2015387986B2 (es)
BR (1) BR112017017189A2 (es)
CA (1) CA2972889C (es)
CL (1) CL2017001262A1 (es)
CO (1) CO2017007046A2 (es)
CR (1) CR20170320A (es)
DO (1) DOP2017000161A (es)
EA (1) EA036702B1 (es)
EC (1) ECSP17056559A (es)
ES (1) ES2850998T3 (es)
GT (1) GT201700149A (es)
HK (1) HK1249426A1 (es)
IL (1) IL253480B (es)
MX (1) MX357998B (es)
MY (1) MY173111A (es)
NZ (1) NZ733186A (es)
PE (1) PE20180228A1 (es)
PH (1) PH12017501157A1 (es)
SG (1) SG11201705163XA (es)
TN (1) TN2017000257A1 (es)
WO (1) WO2016153331A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018193648A1 (ja) * 2017-04-18 2018-10-25 国立大学法人東北大学 アルカリ性化剤による血液浄化
JP7219898B2 (ja) * 2017-04-18 2023-02-09 国立大学法人東北大学 アルカリ性化剤による血液浄化
IT201700087359A1 (it) * 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
IT201700087376A1 (it) 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
AU2019361520A1 (en) * 2018-10-17 2021-05-20 Nippon Chemiphar Co., Ltd. Novel pharmaceutical composition
CN109125310A (zh) * 2018-11-06 2019-01-04 河北工业大学 琥珀酸在抑制Kv10.1离子通道活性中的应用和药物
EP3976559A4 (en) 2019-05-30 2023-06-21 Koch Agronomic Services, LLC FOLIAR SOLUTIONS OF MICRONUTRIENTS
US11666548B2 (en) * 2020-06-05 2023-06-06 Baxter International Inc. Parenteral nutrition formulation
CN115414383A (zh) * 2022-10-14 2022-12-02 青岛普瑞森医药科技有限公司 血液透析浓缩液及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5475031A (en) * 1993-09-03 1995-12-12 Livingston; William H. Discovery of a valuable property for succinic acid and other intermediary metabolites
US5500232A (en) * 1994-10-06 1996-03-19 Bristol-Myers Squibb Company Calcium fortified beverages
US6488961B1 (en) * 1996-09-20 2002-12-03 Ethypharm, Inc. Effervescent granules and methods for their preparation
EP0938849A1 (en) 1998-02-18 1999-09-01 Quest International B.V. A composition with a fresh, fruit like taste
US6288116B1 (en) * 1998-05-13 2001-09-11 Novartis Nutrition Ag Method of administration of a nutritional product to a person having renal failure
WO2001026487A1 (en) * 1999-10-12 2001-04-19 Meiji Seika Kaisha, Ltd. Low potassium juice, method for producing thereof and food containing the same
AU2002211770A1 (en) * 2000-10-16 2002-04-29 Pepsico, Inc. Calcium-supplemented beverages and method of making same
US20030211204A1 (en) * 2002-05-10 2003-11-13 Fields Christine C. Method of preparing beverages and beverage concentrates nutritionally supplemented with minerals
US20090186127A1 (en) * 2004-12-15 2009-07-23 Krumhar Kim C Energy drink compositions
BRPI0602825A2 (pt) * 2006-06-23 2012-04-24 Rhodia Br Ltda formulação de pó efervescente auto-refrigerante para bebidas e uso de formulação em pó efervescente
US20080058421A1 (en) 2006-09-05 2008-03-06 John Alex Lopes Compositions for cleaning and disinfecting nasal tract and sinus cavity
CN105380936A (zh) * 2006-12-12 2016-03-09 味之素株式会社 铁代谢改善剂
CN101568334A (zh) * 2006-12-12 2009-10-28 味之素株式会社 铁代谢改善剂
US20080226799A1 (en) * 2007-03-14 2008-09-18 Concentrate Manufacturing Company Of Ireland Diet Cola Beverages
WO2009032538A1 (en) * 2007-08-31 2009-03-12 C.B. Fleet Company, Inc. Method of preventing nephrocalcinosis
JP5740393B2 (ja) * 2009-05-15 2015-06-24 バイオセプタ コーポレイションｂｉｏＣＥＰＴＡ Ｃｏｒｐｏｒａｔｉｏｎ 皮膚および爪の真菌感染症の局所治療に適した組成物
NL2009407C2 (en) * 2012-09-03 2014-03-04 Dutch Renewable Energy B V Antimicrobial composition.

Also Published As

Publication number Publication date
CR20170320A (es) 2017-08-14
CN108024981A (zh) 2018-05-11
EA036702B1 (ru) 2020-12-09
WO2016153331A1 (es) 2016-09-29
ES2850998T3 (es) 2021-09-02
US20180000764A1 (en) 2018-01-04
NZ733186A (en) 2018-09-28
JP2018505191A (ja) 2018-02-22
AU2015387986B2 (en) 2018-12-20
ECSP17056559A (es) 2017-10-31
US20200138755A1 (en) 2020-05-07
EP3219315A1 (en) 2017-09-20
AU2015387986A1 (en) 2017-07-13
DOP2017000161A (es) 2017-08-31
TN2017000257A1 (en) 2018-10-19
KR102057555B1 (ko) 2019-12-19
CN108024981B (zh) 2021-07-20
GT201700149A (es) 2018-10-25
EP3219315B1 (en) 2020-09-02
HK1249426A1 (zh) 2018-11-02
BR112017017189A2 (pt) 2018-04-03
IL253480B (en) 2020-05-31
CA2972889A1 (en) 2016-09-29
EP3219315A4 (en) 2017-12-06
KR20170104575A (ko) 2017-09-15
PH12017501157B1 (en) 2017-11-27
MX357998B (es) 2018-07-11
CA2972889C (en) 2019-04-23
MX2015003641A (es) 2016-04-08
SG11201705163XA (en) 2017-07-28
JP6771191B2 (ja) 2020-10-21
MY173111A (en) 2019-12-27
IL253480A0 (en) 2017-09-28
PH12017501157A1 (en) 2017-11-27
EA201700339A1 (ru) 2018-02-28
US10688068B2 (en) 2020-06-23
CL2017001262A1 (es) 2017-09-29
PE20180228A1 (es) 2018-01-31

Similar Documents

Publication Publication Date Title
CO2017007046A2 (es) Mezcla de ácidos carboxilicos para tratar pacientes con insuficiencia renal
CY1120928T1 (el) Πρωτεϊνες συντηξης για τη θεραπεια διαταραχων του μεταβολισμου
NZ607189A (en) Materials and methods for improving gastrointestinal function
MX2018013476A (es) Composiciones para tratar trastornos acido-base.
PH12013502027A1 (en) Nutritional compositions having alpha-hica and alpha-ketoglutarate
PH12020500321A1 (en) Amino acid compositions for the treatment of liver disease
ATE412410T1 (de) Verwendung der salze, anlagerungs- und komplexverbindungen der guanidinoessigsäure
EA202091396A1 (ru) Композиции и способы лечения метаболических состояний
GEP20247596B (en) Crystalline forms and salt forms of a kinase inhibitor
NZ599442A (en) Allergy treatment using acid treated aqueous whey protein extract
CL2017003323A1 (es) Composición para el tratamiento de nafld
JOP20200133A1 (ar) طريقة لتحضير حمض (3s)-3-(4-كلورو-3-{[(2s،3r) -2-(4-كلورو فنيل) -4، 4، 4-ثلاثي فلورو-3-مثيل بيوتانويل] أمينو} فنيل) -3- بروبيل حلقي بروبانويك والشكل البلوري منه لاستخدامه كمركب فعال صيدلانياً
MX2009013937A (es) Nuevo uso de compuestos quimicos farmacologicamente activos conocidos.
MX2017004010A (es) Mezcla de oxalacetato, alfacetoglutarato, ácido tartánico y sales de lactato de calcio y sodio, para tratar pacientes con insuficiencia renal crónica.
MX2023005014A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
EA202090728A1 (ru) Применение нор-урсодезоксихолевой кислоты для снижения печеночного жира
MX2016016313A (es) Sumplemento alimenticio a base de ferulato de etilo.
MX2022011206A (es) Composiciones farmaceuticas de sales de ester de colina de acido lipoico y metodos de tratamiento usando las mismas.
BR112018007122A2 (pt) composição nutricional selecionada dentre uma fórmula para bebês e uma fórmula de continuação, e composição nutricional para uso
UA105536U (uk) Спосіб лікування діастолічної дисфункції серця у хворих на цукровий діабет 2 типу, які перенесли не-q-інфаркт міокарда
RU2014109986A (ru) Фармацевтическая композиция для лечения гриппа
GR1008804B (el) Συνθεσεις για ιατρικη χρηση οι οποιες περιλαμβανουν υαλουρονικο οξυ ή αλατα αυτου, αμινοξεα, βιταμινες, ανοργανα αλατα και αλλα συστατικα
MX364490B (es) Composición farmacéutica para el mejoramiento de la condición general de enfermos crónicos con estados de pérdida de energía y proteínas.